Analysts Offer Insights on Healthcare Companies: Kite Pharma (NASDAQ: KITE) and Accelerate Diagnostics (NASDAQ: AXDX)

By Jason Carr

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Kite Pharma (NASDAQ: KITE) and Accelerate Diagnostics (NASDAQ: AXDX).

Kite Pharma (NASDAQ: KITE)

In a report issued on November 9, Dane Leone from BTIG maintained a Hold rating on Kite Pharma (NASDAQ: KITE). The company’s shares closed last Friday at $51.50.

According to TipRanks.com, Leone is a 5-star analyst with an average return of 11.4% and a 70.4% success rate. Leone covers the Healthcare sector, focusing on stocks such as Corvus Pharmaceuticals Inc, Quest Diagnostics Inc., and Trillium Therapeutics.

Kite Pharma has an analyst consensus of Strong Buy, with a price target consensus of $72.

Accelerate Diagnostics (NASDAQ: AXDX)

BTIG analyst Karen Koski maintained a Buy rating on Accelerate Diagnostics (NASDAQ: AXDX) on November 9 and set a price target of $30. The company’s shares closed last Friday at $25.60, close to its 52-week high of $28.50.

According to TipRanks.com, Koski is a 5-star analyst with an average return of 14.1% and a 60.8% success rate. Koski covers the Healthcare sector, focusing on stocks such as Orasure Technologies, Foundation Medicine, and Intuitive Surgical.

Currently, the analyst consensus on Accelerate Diagnostics is Moderate Buy and the average price target is $27.50, representing a 7.4% upside.

In a report issued on November 9, J.P. Morgan also reiterated a Buy rating on the stock with a $25 price target.